ResearcherUniversity of TorontoActive in the last 2 years
Ché M.P. Melo
Matched on ORCID iD 0009-0007-2812-2498; OpenAlex author ID A5000065238. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 3
- Inositol Polyphosphate-4-Phosphatase Type II promotes gemcitabine resistance in pancreatic ductal adenocarcinoma cells via lysosomal exocytosis Co-author DOI 10.64898/2026.08.21.746312↗
- ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.70080↗
- INPP4B promotes PDAC aggressiveness via PIKfyve and TRPML-1-mediated lysosomal exocytosis. Co-author DOI 10.1083/jcb.202401012↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Leonardo Salmena · 3 shared papers, 2024–2026 · strength 0.74
- Paper Inositol Polyphosphate-4-Phosphatase Type II promotes gemcitabine resistance in pancreatic ductal adenocarcinoma cells … DOI 10.64898/2026.08.21.746312↗
- Paper ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma. DOI 10.1002/1878-0261.70080↗
- Paper INPP4B promotes PDAC aggressiveness via PIKfyve and TRPML-1-mediated lysosomal exocytosis. DOI 10.1083/jcb.202401012↗
- Golam T. Saffi · 3 shared papers, 2024–2026 · strength 0.74
- Paper Inositol Polyphosphate-4-Phosphatase Type II promotes gemcitabine resistance in pancreatic ductal adenocarcinoma cells … DOI 10.64898/2026.08.21.746312↗
- Paper ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma. DOI 10.1002/1878-0261.70080↗
- Paper INPP4B promotes PDAC aggressiveness via PIKfyve and TRPML-1-mediated lysosomal exocytosis. DOI 10.1083/jcb.202401012↗
- Daniel K.C. Lee · 1 shared paper, 2025 · strength 0.25
- Steve Gallinger · 1 shared paper, 2024 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.